A new-generation uric acid production inhibitor febuxostat - Comparison of the XO inhibition mechanism with allopurinol

Japanese Pharmacology and Therapeutics

Volumn 38, Issue 11, 2010, Pages 955-962

  Okamoto, Ken ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Allopurinol; Febuxostat; Mechanism of inhibition; Xanthine oxidase inhibitors

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID; XANTHINE OXIDASE;

DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYMOLOGY; GOUT; HYPERURICEMIA; MOLECULAR INTERACTION; REVIEW; SPECTROSCOPY; URIC ACID BLOOD LEVEL;

EID: 78650878342     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Elion GB. Enzymatic and metabolic studies with allopurinol. Ann Rheum Dis 1966 ; 25 : 608-14.
2. Hille R, Massey V. Tight binding inhibitors of xanthine oxidase. Pharmacol Ther 1981 ; 14 : 249-63. (Pubitemid 12193880)
3. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr Med Chem 2002 ; 9 : 195-217.
4. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984 ; 76 : 47-56.
5. Singer S, Elion GB, Hitchings GH. Resistance to inhibitors of dihydrofolate reductase in strains of Lactobacillus casei and Proteus vulgaris. J Gen Microbiol 1966 ; 42 : 185-96.
6. Okamoto K, Nishino T. Mechanism of inhibition of xanthine oxidase with a new tight binding inhibitor. J Biol Chem 1995 ; 270 : 7816-21.
7. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003 ; 278 : 1848-55.
8. Fukunari A, Okamoto K, Nishino T, et al. Y-700 [1- [3-Cyano-4- (2,2-dimethylpropoxy) phenyl]-1H-pyrazole-4-carboxylic acid] : a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther 2004 ; 311 : 519-28. (Pubitemid 39391536)
9. Okamoto K, Matsumoto K, Hille R, Eger BT, Pai EF, Nishino T. The crystal structure of xanthine oxidoreductase during catalysis : implications for reaction mechanism and enzyme inhibition. Proc Natl Acad Sci U S A 2004 ; 101 : 7931-6.
10. Becker MA, Schumacher HR, Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 ; 353 : 2450-61.
11. Bruce SP. Febuxostat : a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006 ; 40 : 2187-94.
12. Elion GB. The purine path to chemotherapy. Science 1989 ; 244 : 41-7.
13. Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol 1966 ; 15 : 863-80.
14. Massey V, Komai H, Palmer G, Elion GB. The existence of nonfunctional active sites in milk xanthine oxidase : reaction with functional active site inhibitors. Vitam Horm 1970 ; 28 : 505-31.
15. Okamoto K. [Inhibitors of xanthine oxidoreductase]. Nippon Rinsho 2008 ; 66 : 748-53.
16. Krenitsky TA, Elion GB, Strelitz RA, Hitchings GH. Ribonucleosides of allopurinol and oxoallopurinol. Isolation from human urine, enzymatic synthesis, and characterization. J Biol Chem 1967 ; 242 : 2675-82.
17. Nelson DJ, Elion GB. Metabolic studies of high doses of allopurinol in humans. Adv Exp Med Biol 1984 ; 165 Pt A : 167-70.
18. Reiter S, Loffler W, Grobner W, Zollner N. Urinary oxipurinol-1-riboside excretion and allopurinol-induced oroticaciduria. Adv Exp Med Biol 1986 ; 195 Pt A : 453-60.
19. Krenitsky TA, Elion GB, Henderson AM, Hitchings GH. Inhibition of human purine nucleoside phosphorylase. Studies with intact erythrocytes and the purified enzyme. J Biol Chem 1968 ; 243 : 2876-81.
20. Kelley WN, Beardmore TD. Allopurinol : alteration in pyrimidine metabolism in man. Science 1970 ; 169 : 388-90.
21. Fyfe JA, Miller RL, Krenitsky TA. Kinetic properties and inhibition of orotidine 5′-phosphate decarboxylase. Effects of some allopurinol metabolites on the enzyme. J Biol Chem 1973 ; 248 : 3801-9.
22. Brown GK, O'Sullivan WJ. Inhibition of human erythrocyte orotidylate decarboxylase. Biochem Pharmacol 1977 ; 26 : 1947-50.
23. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986 ; 29 : 82-7.
24. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993 ; 241 : 183-8.
25. Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 2005 ; 76 : 1835-47.
26. Elion GB, Yu TF, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968 ; 45 : 69-77.
27. Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids 2004 ; 23 : 1117-8.
28. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005 ; 12 : 22-34. (Pubitemid 40516043)
29. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004 ; 51 : 321-5.
30. Kamatani N FS, Hada T, Hosoya T, Matsuzawa Y, Ueda T, Yamanaka H, et al. Febuxostat, a Novel non-purine Selective Inhibitor of Xanthine Oxidase, in a Phase III Placebo-controlled Double-blind Clinical Trial in Japanese Subjects with Gout or Hyperuricemia. Arthritis Rheum 2004 ; 50 Supp : 336-7.